van Baar Michaël J B, van der Aart Annemarie B, Hoogenberg Klaas, Joles Jaap A, Heerspink Hiddo J L, van Raalte Daniël H
Department of Internal Medicine, Amsterdam University Medical Centers, VUMC, Amsterdam, The Netherlands.
Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.
Ther Adv Endocrinol Metab. 2019 Jul 24;10:2042018819865398. doi: 10.1177/2042018819865398. eCollection 2019.
Diabetic kidney disease (DKD) remains the main cause for chronic kidney disease (CKD) and end-stage kidney disease (ESKD) worldwide. Both CKD and ESKD lead to major increases in risk of cardiovascular disease and death in people with diabetes. Despite optimal management of lifestyle, glucose levels and hypertension, residual risk remains high, indicating that additional therapies to mitigate the burden of the disease are desired. In past decades, new treatment options for the management of diabetes have emerged, of which some have showed promising renoprotective potential. This review discusses current understanding of the renal effects of glucagon-like peptide receptor agonists and their potential use in prevention and treatment of DKD.
糖尿病肾病（DKD）仍然是全球慢性肾脏病（CKD）和终末期肾病（ESKD）的主要病因。CKD和ESKD都会大幅增加糖尿病患者患心血管疾病和死亡的风险。尽管对生活方式、血糖水平和高血压进行了优化管理，但残余风险仍然很高，这表明需要额外的治疗方法来减轻该疾病的负担。在过去几十年中，出现了用于治疗糖尿病的新选择，其中一些已显示出有前景的肾脏保护潜力。本综述讨论了目前对胰高血糖素样肽受体激动剂肾脏效应的理解及其在DKD预防和治疗中的潜在用途。
